These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Long-term protective immunity induced by an adjuvant-containing live-attenuated AIDS virus. Okamura T; Shimizu Y; Asaka MN; Kanuma T; Tsujimura Y; Yamamoto T; Matsuo K; Yasutomi Y NPJ Vaccines; 2021 Oct; 6(1):124. PubMed ID: 34686680 [TBL] [Abstract][Full Text] [Related]
47. Long-term central and effector SHIV-specific memory T cell responses elicited after a single immunization with a novel lentivector DNA vaccine. Arrode-Brusés G; Moussa M; Baccard-Longere M; Villinger F; Chebloune Y PLoS One; 2014; 9(10):e110883. PubMed ID: 25337803 [TBL] [Abstract][Full Text] [Related]
48. Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques. Arrode-Brusés G; Hegde R; Jin Y; Liu Z; Narayan O; Chebloune Y Vaccine; 2012 Apr; 30(19):2956-62. PubMed ID: 22387218 [TBL] [Abstract][Full Text] [Related]
49. Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. Berry N; Ham C; Mee ET; Rose NJ; Mattiuzzo G; Jenkins A; Page M; Elsley W; Robinson M; Smith D; Ferguson D; Towers G; Almond N; Stebbings R PLoS One; 2011; 6(8):e23092. PubMed ID: 21853072 [TBL] [Abstract][Full Text] [Related]
51. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development? Sealy R; Zhan X; Lockey TD; Martin L; Blanchard J; Traina-Dorge V; Hurwitz JL Curr HIV Res; 2009 Sep; 7(5):497-503. PubMed ID: 19925400 [TBL] [Abstract][Full Text] [Related]
52. Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine. Arrode-Brusés G; Sheffer D; Hegde R; Dhillon S; Liu Z; Villinger F; Narayan O; Chebloune Y J Virol; 2010 Feb; 84(3):1243-53. PubMed ID: 19923181 [TBL] [Abstract][Full Text] [Related]
53. Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge. Busch M; Abel K; Li J; Piatak M; Lifson JD; Miller CJ Vaccine; 2005 Jul; 23(31):4036-47. PubMed ID: 15963361 [TBL] [Abstract][Full Text] [Related]
54. Live attenuated AIDS viruses as vaccines: promise or peril? Ruprecht RM Immunol Rev; 1999 Aug; 170():135-49. PubMed ID: 10566148 [TBL] [Abstract][Full Text] [Related]
55. Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques. Yankee TM; Sheffer D; Liu Z; Dhillon S; Jia F; Chebloune Y; Stephens EB; Narayan O Virology; 2009 Jan; 383(1):103-11. PubMed ID: 18986665 [TBL] [Abstract][Full Text] [Related]
56. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P). Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906 [TBL] [Abstract][Full Text] [Related]
57. Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus. Mackay GA; Liu Z; Singh DK; Smith MS; Mukherjee S; Sheffer D; Jia F; Adany I; Sun KH; Dhillon S; Zhuge W; Narayan O J Immunol; 2004 Sep; 173(6):4100-7. PubMed ID: 15356160 [TBL] [Abstract][Full Text] [Related]